Friday, 15 November 2024
  
Login

Australia's most trusted
source of pharma news

Friday, 15 November 2024
News

Is this pharma quietly for sale?

Posted 11 November 2024 PM

ASX-listed Mayne Pharma is remaining tight-lipped about media reports the company is being marketed to potential buyers in the hope of securing a lucrative exit for its shareholders who have seen their investment plumet in recent years.

The Australian Financial Review's Street Talk column, reported that investment bank Jeffries Australia is quietly shopping the pharma around with sources also noting that the company had been actively presenting at global healthcare conferences, including events hosted by Jefferies, JPMorgan, and HC Wainwright, suggesting that Mayne is keen to attract potential investors.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (15)

Access & Reimbursement (1)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (1)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.